{
  "nctId": "NCT04311086",
  "briefTitle": "SPYRAL DYSTAL Renal Denervation Global Clinical Study",
  "officialTitle": "Global Clinical Study of Renal Denervation in the Distal Main and First Order Branch Renal Arteries Using the Symplicity Spyral™ Multi-electrode Renal Denervation System (SPYRAL DYSTAL)",
  "protocolDocument": {
    "nctId": "NCT04311086",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2022-03-14",
    "uploadDate": "2024-02-01T09:33",
    "size": 1448293,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT04311086/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "NA"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "NA",
  "interventionModel": "SINGLE_GROUP",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 128,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2020-06-12",
    "completionDate": "2022-12-22",
    "primaryCompletionDate": "2022-12-22",
    "firstSubmitDate": "2020-03-12",
    "firstPostDate": "2020-03-17"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n\\- Individual has office systolic blood pressure (SBP) ≥ 150 mmHg and \\<180 mmHg and a diastolic blood pressure (DBP) ≥ 90 mmHg after being off medications.\n\n* Individual has 24-hour Ambulatory Blood Pressure Monitoring (ABPM) average SBP ≥ 140 mmHg and \\< 170 mmHg.\n* Individual is willing to discontinue current antihypertensive medications\n\nExclusion Criteria:\n\n* Individual has estimated glomerular filtration rate (eGFR) of \\<45.\n* Individual has type 1 diabetes mellitus or poorly-controlled type 2 diabetes mellitus.\n* Individual has one or more episodes of orthostatic hypotension.\n* Individual requires chronic oxygen support or mechanical ventilation other than nocturnal respiratory support for sleep apnea.\n* Individual has primary pulmonary hypertension.\n* Individual is pregnant, nursing or planning to become pregnant.\n* Individual has frequent intermittent or chronic pain that results in treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) for two or more days per week over the month prior to enrollment.\n* Individual has stable or unstable angina within 3 months of enrollment, myocardial infarction within 3 months of enrollment; heart failure, cerebrovascular accident or transient ischemic attack, or atrial fibrillation at any time.\n* Individual works night shifts.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "20 Years",
    "maximumAge": "80 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Change in Systolic Blood Pressure (SBP) as Measured by 24-hour Ambulatory Blood Pressure Monitoring (ABPM)",
        "timeFrame": "From Baseline (SV2) to 12 months post-procedure"
      }
    ],
    "secondary": [
      {
        "measure": "Change in Systolic Blood Pressure (SBP) as Measured by 24-hour Ambulatory Blood Pressure Monitoring (ABPM)",
        "timeFrame": "From Baseline (SV2) to 3 months post-procedure"
      },
      {
        "measure": "Change in Office Systolic Blood Pressure (SBP)",
        "timeFrame": "From Baseline (SV2) to 3 months post-procedure"
      },
      {
        "measure": "Change in Office Systolic Blood Pressure (SBP)",
        "timeFrame": "From Baseline (SV2) to 12 months post-procedure"
      },
      {
        "measure": "Change in Diastolic Blood Pressure (DBP) as Measured by 24-hour Ambulatory Blood Pressure Monitoring (ABPM)",
        "timeFrame": "From Baseline (SV2) to 3 months post-procedure"
      },
      {
        "measure": "Change in Diastolic Blood Pressure (DBP) as Measured by 24-hour Ambulatory Blood Pressure Monitoring (ABPM)",
        "timeFrame": "From Baseline (SV2) to 12 months post-procedure"
      },
      {
        "measure": "Change in Office Diastolic Blood Pressure (DBP)",
        "timeFrame": "From Baseline (SV2) to 3 month post-procedure"
      },
      {
        "measure": "Change in Office Diastolic Blood Pressure (DBP)",
        "timeFrame": "From Baseline (SV2) to 12 months post-procedure"
      },
      {
        "measure": "Incidence of Achieving Target Office Systolic Blood Pressure (SBP)",
        "description": "Target blood pressure defined as \\<140 mmHg office Systolic Blood Pressure (SBP)",
        "timeFrame": "3 months post-procedure"
      },
      {
        "measure": "Incidence of Achieving Target Office Systolic Blood Pressure (SBP)",
        "description": "Target blood pressure defined as \\<140 mmHg office Systolic Blood Pressure (SBP)",
        "timeFrame": "12 months post-procedure"
      },
      {
        "measure": "Acute and Chronic Safety by Evaluating Incidence of Major Adverse Events",
        "description": "Incidence of the following events:\n\n* All-cause mortality\n* End-stage renal disease (ESRD)\n* Significant embolic event resulting in end-organ damage\n* Renal artery perforation requiring intervention\n* Renal artery dissection requiring intervention\n* Vascular complications\n* Hospitalization for hypertensive crisis not related to confirmed non-adherence with medications or the protocol\n* New renal artery stenosis \\>70%, confirmed by angiography and as determined by the angiographic core lab at 6 months follow up",
        "timeFrame": "From Baseline (SV2) to 12 months post-procedure"
      },
      {
        "measure": "Incidence of Myocardial Infarction",
        "description": "Defined as the concurrent documentation of two of the three elements listed below in the appropriate clinical circumstance:\n\n1. Chest pain or ischemic equivalent\n2. New pathologic q waves in at least 2 contiguous ECG leads\n3. Cardiac biomarker elevation by any of the definitions below:\n\nAppropriate cardiac enzyme data (respecting top-down hierarchy):\n\n1. CK greater than or equal to 2\\* URL confirmed by:\n\n   * CKMB \\> l\\*URL or\n   * in the absence of CKMB: Troponin \\> l\\*URL or\n2. in the absence of CK:\n\n   * CKMB \\> 3\\*URL\n   * In the absence of CK and CKMB: Troponin \\> 3\\*URL\n   * In the absence of CK, CKMB and Troponin, clinical decision based upon clinical scenario",
        "timeFrame": "From baseline (SV2) to 12 months post-procedure"
      },
      {
        "measure": "Incidence of Stroke",
        "timeFrame": "From baseline (SV2) to 12 months post-procedure"
      },
      {
        "measure": "Incidence of Renal Artery Re-intervention",
        "description": "Interventional procedure performed on the renal artery following completion of the renal denervation procedure and removal of the guide catheter.",
        "timeFrame": "From baseline (SV2) to 12 months post-procedure"
      },
      {
        "measure": "Incidence of Major Bleeding According to TIMI Definition",
        "description": "Intracranial hemorrhage; ≥5g/dl decrease in hemoglobin concentration, a ≥15% absolute decrease in hematocrit, or death due to bleeding within seven days of the procedure)",
        "timeFrame": "From baseline (SV2) to 12 months post-procedure"
      },
      {
        "measure": "Incidence of Increase in Serum Creatinine >50%",
        "timeFrame": "From baseline (SV2) to 12 months post-procedure"
      }
    ],
    "other": [
      {
        "measure": "Reduction in Systolic Blood Pressure (SBP) Over 24 Hours of ABPM as Measured With 24- Ambulatory Blood Pressure Monitor (ABPM) at 3 Months Post-procedure From Baseline",
        "description": "Comparison of systolic blood pressure reduction over 24 hours of ABPM between the SPYRAL DYSTAL study and the SPYRAL HTN-OFF MED study (NCT02439749) who, after a renal angiography according to standard procedures, are treated with the renal denervation procedure.",
        "timeFrame": "3 months post-procedure"
      },
      {
        "measure": "Reduction in Diastolic Blood Pressure (DBP) Over 24 Hours as Measured With 24-Ambulatory Blood Pressure Monitor (ABPM) at 3 Months Post-procedure From Baseline",
        "description": "Comparison of diastolic blood pressure reduction over 24 hours of ABPM between the SPYRAL DYSTAL study and the SPYRAL HTN-OFF MED study (NCT02439749) who, after a renal angiography according to standard procedures, are treated with the renal denervation procedure.",
        "timeFrame": "3 Months post-procedure"
      },
      {
        "measure": "Office Systolic Blood Pressure (SBP) Reduction",
        "description": "Comparison of Office Systolic Blood Pressure (SBP) reduction between the SPYRAL DYSTAL study and the SPYRAL HTN-OFF MED study (NCT02439749) who, after a renal angiography according to standard procedures, are treated with the renal denervation procedure.",
        "timeFrame": "From Baseline (SV2) to 3 months post-procedure"
      },
      {
        "measure": "Office Diastolic Blood Pressure (DBP) Reduction",
        "description": "Comparison of Office Diastolic Blood Pressure (DBP) reduction between the SPYRAL DYSTAL study and the SPYRAL HTN-OFF MED study (NCT02439749) who, after a renal angiography according to standard procedures, are treated with the renal denervation procedure.",
        "timeFrame": "From Baseline (SV2) to 3 months post-procedure"
      },
      {
        "measure": "Procedural Characteristics: Procedure Time (Minutes)",
        "description": "Comparison of procedural characteristics: total procedure duration (minutes) between the SPYRAL DYSTAL study and the SPYRAL HTN-OFF MED study (NCT02439749) who, after a renal angiography according to standard procedures, are treated with the renal denervation procedure.",
        "timeFrame": "Procedure"
      },
      {
        "measure": "Procedural Characteristics: Denervation Time (Minutes)",
        "description": "Comparison of the procedural characteristics: total denervation time between the SPYRAL DYSTAL study and the SPYRAL HTN-OFF MED study (NCT02439749) who, after a renal angiography according to standard procedures, are treated with the renal denervation procedure.",
        "timeFrame": "Procedure"
      },
      {
        "measure": "Procedural Characteristics: Amount of Contrast Used (cc)",
        "description": "Comparison of the procedural characteristics: amount of contrast used (cubic centimeter(cc)) between the SPYRAL DYSTAL study and the SPYRAL HTN-OFF MED study (NCT02439749) who, after a renal angiography according to standard procedures, are treated with the renal denervation procedure.",
        "timeFrame": "Procedure"
      }
    ]
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 15,
      "otherCount": 7,
      "totalCount": 23
    },
    "studyDesign": {
      "phases": [
        "NA"
      ],
      "isRandomized": false,
      "isMasked": false,
      "interventionModel": "SINGLE_GROUP"
    },
    "overallComplexityScore": 100,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:30:07.771Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}